Alexion is focused on serving patients and families affected by rare diseases by delivering innovative, life-changing therapies. In 2007, Alexion began operations in the UK to serve patients locally. Our approach to serving patients is driven by education and a passion for understanding and meeting the unique needs of patients and families suffering from rare diseases. We are driven because we know people’s lives depend on our work.
In the UK, Alexion has therapies available for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), pediatric onset hypophosphatasia (HPP), and lysosomal acid lipase deficiency (LAL-D).
Transparency & Disclosure
Alexion is committed to operating with integrity, accountability, and transparency, and to complying with all applicable laws and regulations. Further information on disclosure can be found here.
Financial contributions to UK and Irish PAOs from 2015 – 2018
Financial contributions to UK and Irish PAOs can be found here.
Working at Alexion is an experience like no other. With a focus on rare diseases that have few, if any, effective treatments, each endeavor is urgent and every day counts. Groundbreaking innovation and life-saving therapies, driven by a team with a shared sense of purpose and dedication — that’s Alexion.